Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies
Contact us

News

Stay up to date with the exciting new developments as we continue to grow.

The content of all investor relations materials contained on this website are deemed to be correct at the time of issue/publication.

Filter by date

6 Aug 2020

Shield provides the headline results from the reanalysis of the AEGIS-H2H study.

Shield Therapeutics plc, provides the headline results from the reanalysis of the AEGIS-H2H study. For further details click here.

26 May 2020

Appointment of Chairman

Shield Therapeutics plc, announces the appointment of Hans Peter Hasler as non-executive Chairman of the Company with effect from the Annual General Meeting (‘AGM’) on…

22 May 2020

2019 Annual Report and 2020 AGM Notice

Shield Therapeutics plc, announces that the following documents have now been sent to shareholders: Annual Report and Accounts for the year ended 31 December 2019…

21 May 2020

Preliminary Results for the Year Ended 31 December 2019

Shield Therapeutics plc, announces its preliminary Group results for the year ended 31 December 2019. For full details click here.

19 May 2020

Notice of results

Shield Therapeutics plc, will announce its preliminary results for the year ended 31 December 2019 on Thursday 21 May 2020. For further details click here.

1 May 2020

Shield Therapeutics plc – Business and Trading Update

Shield Therapeutics plc, provides a business and unaudited trading update, to view the full update please click here.

22 Apr 2020

Directorate Change

Shield Therapeutics plc, announces that, following discussions with major shareholders and with mutual agreement, Carl Sterritt has informed the Company of his decision to resign…

17 Mar 2020

AEGIS-H2H study update

Shield Therapeutics plc, today provides an update and clarification relating to the AEGIS-H2H clinical trial, the data from which was primarily designed to be used…

8 Jan 2020

Shield Therapeutics announces exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co. Ltd in China.

Shield Therapeutics plc,  announces that it has entered into an exclusive licence agreement for its lead product Feraccru®/Accrufer® (ferric maltol) with Beijing Aosaikang Pharmaceutical Co.…